Pharmacy Prior Authorization Criteria

Revuforj (revumenib)

Indications for Prior Authorization

Revuforj (revumenib)

• For diagnosis of Relapsed or Refractory Acute Leukemia
  Indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Criteria

Revuforj

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

• Diagnosis of acute leukemia
AND
• Disease is relapsed or refractory
AND
• Patient is 1 year of age or older
AND
• Presence of lysine methyltransferase 2A gene (KMT2A) translocation

Revuforj

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

• Patient does not show evidence of progressive disease while on therapy

P & T Revisions

2025-04-14, 2024-12-24

References

1. Revuforj Prescribing Information. Syndax Pharmaceuticals, Inc. November 2024

---

Revision History

• 2025-04-14: Added Revuforj 25mg to guideline
• 2024-12-24: New Program.

---